Phase III clinical trial went very smoothly, vaccine could be ready by November/December – Global Times
|Ordinary Chinese could take the #COVID19 vaccine as early as November or December as the phase III clinical trial went very smoothly: Chinese CDC chief biosafety expert pic.twitter.com/wrYqvgzA7p
— Global Times (@globaltimesnews) September 15, 2020
Ordinary Chinese could take the #COVID19 vaccine as early as November or December as the phase III clinical trial went very smoothly: Chinese CDC chief biosafety expert pic.twitter.com/wrYqvgzA7p
— Global Times (@globaltimesnews) September 15, 2020
The Global Times has tweeted the update in recent trade, although there have been zero uptakes on the headline in markets.
Researchers around the world are racing to develop a vaccine against Covid-19, with more than 170 candidate vaccines now tracked by the World Health Organization (WHO).
In phase 3 trials, the vaccine is usually given to thousands of people to confirm its safety – including rare side effects – and effectiveness. These trials involve a control group which is given a placebo.
To date, more broadly speaking, scientists have been hoping to develop a coronavirus vaccine within 12 to 18 months.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.